2. Search Result
Search Result
Results for "

Lactosylceramide

" in MedChemExpress (MCE) Product Catalog:

36

Inhibitors & Agonists

2

Fluorescent Dyes

2

Biochemical Assay Reagents

9

Peptides

2

Natural
Products

1

Isotope-Labeled Compounds

Cat. No. Nombre del producto Target Áreas de investigación Chemical Structure
  • HY-P4070
    Insulin icodec

    		Insulin Receptor Metabolic Disease
    Insulin icodec is an Insulin (HY-P0035) analog that strongly but reversibly binds to albumin. Insulin icodec has long plasma half-life. Insulin icodec modulates insulin receptor activity, controls blood glucose levels, reduces HbA1c levels, and binds reversibly to human serum albumin. Insulin icodec can be used for the research of type 2 diabetes mellitus .
    Insulin icodec
  • HY-P1103
    CTCE-9908
    1 Publications Verification

    		 CXCR Cancer
    CTCE-9908 is a potent and selective CXCR4 antagonist. CTCE-9908 induces mitotic catastrophe, cytotoxicity and inhibits migration in CXCR4-expressing ovarian cancer cells .
    CTCE-9908
  • HY-153830
    LacCer (d18:1/16:0)

    C16 Lactosylceramide (d18:1/16:0)

    		 Endogenous Metabolite Neurological Disease Metabolic Disease
    LacCer (d18:1/16:0) (C16 Lactosylceramide (d18:1/16:0)) is an endogenous bioactive sphingolipid that can form membrane microdomains with Lyn kinase and the αi subunits of inhibitory G protein-coupled receptors (GPCRs). The levels of LacCer (d18:1/16:0) are elevated in the plasma of insulin-resistant cattle. In a mouse model of Niemann-Pick type C1 disease (a neurodegenerative cholesterol-sphingolipid lysosomal storage disorder), the expression of LacCer (d18:1/16:0) is also upregulated. LacCer (d18:1/16:0) can be used in research on metabolic diseases and neurodegenerative diseases .
    LacCer (d18:1/16:0)
  • HY-154921
    Lactosylceramide (bovine buttermilk)

    LacCer (bovine buttermilk)

    		 Reactive Oxygen Species (ROS) Inflammation/Immunology
    Lactosylceramide (bovine buttermilk) (LacCer (bovine buttermilk)) is a sphingolipid that highly expressed on the plasma membranes of human phagocytes. Lactosylceramide mediates phagocytosis, chemotaxis, and superoxide generation .
    Lactosylceramide (bovine buttermilk)
  • HY-E70047
    alpha-1,4-Galactosyltransferase (LgtC)

    A4GALT

    		 Glycosyltransferase Metabolic Disease
    alpha-1,4-Galactosyltransferase (LgtC) (A4GALT) is a glycosphingolipid-specific glycosyltransferase. alpha-1,4-Galactosyltransferase (LgtC) transfers a galactose to the alpha-1,4 position of lactosylceramide to form globotriaosylceramide. alpha-1,4-Galactosyltransferase (LgtC) can be used for the synthesis of P1 blood group antigens .
    alpha-1,4-Galactosyltransferase (LgtC)
  • HY-D1577
    C6 NBD Lactosylceramide

    		Fluorescent Dye Cancer
    C6 NBD Lactosylceramide is a derivative of lactosylceramides, and can be used in lactosylceramide synthase assay as a fluorescent acceptor substrate. C6 NBD Lactosylceramide can also be used in cancer research .
    C6 NBD Lactosylceramide
  • HY-177888
    Lc2Cer(d18:1, 22:0)

    		Biochemical Assay Reagents Endocrinology
    Lc2Cer(d18:1, 22:0) is a lactosylceramide containing d18:1, C22:0 ceramides. Lc2Cer(d18:1, 22:0) can be used for renal cortical epithelial cell research .
    Lc2Cer(d18:1, 22:0)
  • HY-N10526
    Isoglobotriaose

    Gala-3Galb-4Glc

    		 Others Others
    Isoglobotriaose (Gala-3Galb-4Glc) is a glycosphingolipid found in mammalian tissues. Isoglobotriaose is an analogue of Globotriaose, the ganglioside derivatives of them locate in difference position of small intestine, isoglobotriaosylceramide is restricted to the nonepithelial residue, while globotriaosylceramide is in both compartments .
    Isoglobotriaose
  • HY-D1580
    C12 NBD Lactosylceramide

    		Fluorescent Dye Others
    C12 NBD Lactosylceramide is a derivative of Lactosylceramide labeled with a C12 NBD fluorescent group. C12 NBD Lactosylceramide can be used to identify Lactosylceramides .
    C12 NBD Lactosylceramide
  • HY-131701
    Lactosyl-C18-sphingosine

    C18 Lactosyl(β) Ceramide; Lactosyl Sphingosine; Lyso-Lactosylceramide (synthetic)

    		 Endogenous Metabolite Metabolic Disease
    Lactosyl-C18-sphingosine (C18 Lactosyl(β) Ceramide; Lactosyl Sphingosine) is a bioactive sphingolipid that is a form of lactosylceramide but lacks the fatty acyl group. Lysolactosylceramide (1-50 μM) reduces the viability of human neutrophils in a concentration-dependent manner. Unlike lactosylceramide, Lactosyl-C18-sphingosine has no effect on protein synthesis and cell proliferation in cardiomyocytes. Lactosyl-C18-sphingosine is a lysoganglioside GM3.
    Lactosyl-C18-sphingosine
  • HY-153830S
    LacCer (d18:1/16:0)-d3

    C16 Lactosylceramide (d18:1/16:0)-d3

    		 Isotope-Labeled Compounds Endogenous Metabolite Neurological Disease Metabolic Disease
    LacCer (d18:1/16:0) (C16 Lactosylceramide (d18:1/16:0))-d3 is the deuterium labeled LacCer (d18:1/16:0) (HY-153830). LacCer (d18:1/16:0) is an endogenous bioactive sphingolipid that can form membrane microdomains with Lyn kinase and the αi subunits of inhibitory G protein-coupled receptors (GPCRs). LacCer (d18:1/16:0) are elevated in the plasma of insulin-resistant cattle. LacCer (d18:1/16:0) is also upregulated in a mouse model of Niemann-Pick type C1 disease (a neurodegenerative cholesterol-sphingolipid lysosomal storage disorder). LacCer (d18:1/16:0) can be used in research on metabolic diseases and neurodegenerative diseases .
    LacCer (d18:1/16:0)-d3
  • HY-112488
    EXEL-0346

    		Glucosylceramide Synthase (GCS) Metabolic Disease
    EXEL-0346 is an orally active glucosylceramide synthase (GCS) inhibitor, with an IC50 of 2 nM. EXEL-0346 combined with insulin increases pAkt. EXEL-0346 effectively reduces the levels of Glucosylceramide, Lactosylceramide and GM3. EXEL-0346 improves obesity and diabetes .
    EXEL-0346
  • HY-137798
    Chromozym PL

    		Fluorescent Dye Others
    Chromozym PL is a chromogenic substrate for plasmin, and the enzymatic reaction can be carried out in 0.1mL Tris-HCl buffer (50 mM, pH 7.8). 100 μM Chromozym PL was dissolved and prepared. After adding the hydrolase, the generation of p-nitroaniline (pNA) at 405 nm was continuously observed, and the hydrolysis products were calculated .
    Chromozym PL
  • HY-P1103A
    CTCE-9908 TFA

    		CXCR Cancer
    CTCE-9908 TFA is a potent and selective CXCR4 antagonist. CTCE-9908 TFA induces mitotic catastrophe, cytotoxicity and inhibits migration in CXCR4-expressing ovarian cancer cells .
    CTCE-9908 TFA
  • HY-P4757
    N1-Glutathionyl-spermidine disulfide

    		Parasite Others
    N1-Glutathionyl-spermidine disulfide is a substrate of trypanothione reductase .
    N1-Glutathionyl-spermidine disulfide
  • HY-P11293
    DOTA-GGNle-CycMSHhex

    		Melanocortin Receptor Cancer
    DOTA-GGNle-CycMSHhex is a melanocortin-1 receptor (MC1R)-targeting peptide that can be radionuclide-labeled for melanoma imaging .
    DOTA-GGNle-CycMSHhex
  • HY-P1321
    GR231118

    1229U91; GW1229

    		 Neuropeptide Y Receptor Neurological Disease
    GR231118, an analogue of the C-terminus of neuropeptide Y, is a potent , competitive and relative seletive antagonist at human neuropeptide Y Y receptor with a pKi of 10.4. GR231118 a potent agonist at the human neuropeptide Y Y4 receptor (pEC50=8.6; pKi=9.6) and a weak agonist at the human and rat neuropeptide YY2 and Y5 receptors. GR231118 also has high affinity for the mouse neuropeptide Y Y6 receptor (pKi= 8.8) .
    GR231118
  • HY-166121
    N-Hexanoyl-biotin-lactosylceramide

    		Biochemical Assay Reagents Metabolic Disease
    N-Hexanoyl-biotin-lactosylceramide is an ester product.
    N-Hexanoyl-biotin-lactosylceramide
  • HY-154921A
    Lactosylceramide (porcine RBC)

    LacCer (porcine RBC)

    		 Endogenous Metabolite Inflammation/Immunology
    Lactosylceramide (LacCer) (porcine RBC) is an endogenous bioactive sphingolipid. Lactosylceramide (porcine RBC) plays a pivotal role in mediating innate immune functions .
    Lactosylceramide (porcine RBC)
  • HY-E70049
    beta-1,4-N-Acetylgalactosaminyltransferase (CgtA)

    GM2/GD2 synthase

    		 Others Neurological Disease
    beta-1,4-N-Acetylgalactosaminyltransferase (CgtA) (GM2/GD2 synthase) is a key enzyme which catalyzes the conversion of GM3, GD3 and lactosylceramide (LacCer) to GM2, GD2 and asialo-GM2 (GA2), respectively. beta-1,4-N-Acetylgalactosaminyltransferase (CgtA) is a key enzyme to control the synthesis of brain-enriched complex gangliosides .
    beta-1,4-N-Acetylgalactosaminyltransferase (CgtA)
  • HY-P1321A
    GR231118 TFA

    1229U91 TFA; GW1229 TFA

    		 Neuropeptide Y Receptor Neurological Disease
    GR231118 TFA, an analogue of the C-terminus of neuropeptide Y, is a potent , competitive and relative seletive antagonist at human neuropeptide YY receptor with a pKi of 10.4. GR231118 a potent agonist at the human neuropeptide YY4 receptor (pEC50=8.6; pKi=9.6) and a weak agonist at the human and rat neuropeptide Y Y2 and Y5 receptors. GR231118 also has high affinity for the mouse neuropeptide YY6 receptor (pKi= 8.8) .
    GR231118 TFA
  • HY-145465
    C17 Lactosylceramide (d18:1/17:0)

    		Others Metabolic Disease
    C17 Lactosylceramide (d18:1/17:0) is a lipid that can be used to prepare lipid nanoparticles (LNPs) for drug delivery.
    C17 Lactosylceramide (d18:1/17:0)
  • HY-158941
    C18 3'-Sulfo lactosylceramide (d18:1/18:0)

    		Drug Derivative Others
    C18 3'-sulfo Lactosylceramide (d18:1/18:0) is a sulfated glycosphingolipid.
    C18 3'-Sulfo lactosylceramide (d18:1/18:0)
  • HY-P2869J
    β-Galactosidase, Kluyveromyces lactis

    		Biochemical Assay Reagents Metabolic Disease
    β-Galactosidase, Kluyveromyces lactis is a hydrolase enzyme that catalyzes the hydrolysis of β-galactosides into monosaccharides. SubstRates of different β-galactosidases include ganglioside GM1, lactosylceramides, lactose, and various glycoproteins.
    β-Galactosidase, Kluyveromyces lactis
  • HY-E70890
    β-Galactosidase Mutein, E. coli

    		Glycosidase Metabolic Disease
    β-Galactosidase Mutein, E. coli is a hydrolase enzyme that catalyzes the hydrolysis of β-galactosides into monosaccharides. Substrates of different β-galactosidases include ganglioside GM1, lactosylceramides, lactose, and various glycoproteins.
    β-Galactosidase Mutein, E. coli
  • HY-E71027
    β-Galactosidase-biotin labeled, Escherichia coli

    		Biochemical Assay Reagents Metabolic Disease
    β-Galactosidase-biotin labeled, Escherichia coli is a hydrolase enzyme that catalyzes the hydrolysis of β-galactosides into monosaccharides. SubstRates of different β-galactosidases include ganglioside GM1, lactosylceramides, lactose, and various glycoproteins.
    β-Galactosidase-biotin labeled, Escherichia coli
  • HY-181469
    C2 Adamantanyl glucosylceramide (d18:1/2:0)

    Adamantanyl GluCer (d18:1/2:0); Adamantanyl glucosylceramide (d18:1/2:0); AdaGluCer (d18:1/2:0)

    		 Glycosidase Metabolic Disease
    C2 Adamantanyl glucosylceramide (d18:1/2:0) (Adamantanyl GluCer (d18:1/2:0)) is an inhibitor of glucocerebrosidase (GCC) and LacCer synthase. At low doses, C2 Adamantanyl glucosylceramide (d18:1/2:0) increases intracellular glycolipid levels by inhibiting glucocerebrosidase. C2 Adamantanyl glucosylceramide (d18:1/2:0) alters glycolipid metabolism. C2 Adamantanyl glucosylceramide (d18:1/2:0) can be used for the research of Gaucher disease and Fabry disease .
    C2 Adamantanyl glucosylceramide (d18:1/2:0)
  • HY-E71299
    β-Galactosidase 42A, Bifidobacterium longum

    		Glycosidase Others
    β-Galactosidase 42A, Bifidobacterium longum (EC 3.2.1.23) is a hydrolase enzyme that catalyzes the hydrolysis of β-galactosides into monosaccharides. Substrates of different β-galactosidases include ganglioside GM1, lactosylceramides, lactose, and various glycoproteins.
    β-Galactosidase 42A, Bifidobacterium longum
  • HY-E71299B
    β-Galactosidase 42A, Thermotoga maritima

    		Glycosidase Others
    β-Galactosidase 42A, Thermotoga maritima (EC 3.2.1.23) is a hydrolase enzyme that catalyzes the hydrolysis of β-galactosides into monosaccharides. Substrates of different β-galactosidases include ganglioside GM1, lactosylceramides, lactose, and various glycoproteins.
    β-Galactosidase 42A, Thermotoga maritima
  • HY-E71297
    β-Galactosidase 2A, Bacteroides thetaiotaomicron

    		Glycosidase Others
    β-Galactosidase 2A, Bacteroides thetaiotaomicron (EC 3.2.1.23) is a hydrolase enzyme that catalyzes the hydrolysis of β-galactosides into monosaccharides. Substrates of different β-galactosidases include ganglioside GM1, lactosylceramides, lactose, and various glycoproteins.
    β-Galactosidase 2A, Bacteroides thetaiotaomicron
  • HY-E71296
    β-Galactosidase 1A, Sulfolobus solfataricus

    		Glycosidase Others
    β-Galactosidase 1A, Sulfolobus solfataricus (EC 3.2.1.23) is a hydrolase enzyme that catalyzes the hydrolysis of β-galactosides into monosaccharides. Substrates of different β-galactosidases include ganglioside GM1, lactosylceramides, lactose, and various glycoproteins.
    β-Galactosidase 1A, Sulfolobus solfataricus
  • HY-E71299A
    β-Galactosidase 42A, Caldicellulosiruptor saccharolyticus

    		Glycosidase Others
    β-Galactosidase 42A, Caldicellulosiruptor saccharolyticus (EC 3.2.1.23) is a hydrolase enzyme that catalyzes the hydrolysis of β-galactosides into monosaccharides. Substrates of different β-galactosidases include ganglioside GM1, lactosylceramides, lactose, and various glycoproteins.
    β-Galactosidase 42A, Caldicellulosiruptor saccharolyticus
  • HY-E71298
    β-Galactosidase 2B, Bacteroides thetaiotaomicron

    		Glycosidase Others
    β-Galactosidase 2B, Bacteroides thetaiotaomicron (EC 3.2.1.23) is a hydrolase enzyme that catalyzes the hydrolysis of β-galactosides into monosaccharides. Substrates of different β-galactosidases include ganglioside GM1, lactosylceramides, lactose, and various glycoproteins.
    β-Galactosidase 2B, Bacteroides thetaiotaomicron
  • HY-E71025
    β 1-4,6-Galactosidase, Jack bean

    		Biochemical Assay Reagents Metabolic Disease
    β 1-4,6-Galactosidase, Jack bean (EC 3.2.1.23) is a hydrolase enzyme that catalyzes the hydrolysis of β-galactosides into monosaccharides. Substrates of different β-galactosidases include ganglioside GM1, lactosylceramides, lactose, and various glycoproteins.
    β 1-4,6-Galactosidase, Jack bean
  • HY-P11480
    TrkA/NGF-IN-1

    		Trk Receptor Neurological Disease
    TrkA/NGF-IN-1 (Peptide 19) is an inhibitor of protein-protein interactions between TrkA and NGF (IC50: 21 nM for human TrkA in PathHunter assay). TrkA/NGF-IN-1 shows an analgesic effect in a rat incisional pain model .
    TrkA/NGF-IN-1
  • HY-180371
    NF-115

    		Drug Derivative Cancer
    NF-115 is a glycolipid inhibitor. NF-115 inhibits proliferation of glioma cancer cells and exhibits potent antimitotic activity in human astroblastoma cells. NF-115 can be used for research on glioma .
    NF-115

Consulta en línea

Your information is safe with us. * Required Fields.

Saludo

  

Country or Region *

Nombre del solicitante *

 

Nombre de la Organizaciòn *

Department *

     

Direcciòn del E-mail *

 

Nombre del producto *

Cat. No.

  

Requested quantity *

Número de teléfono *

     

Observaciones

Consulta en línea

Inquiry Information

Nombre del producto:
Cat. No.:
Cantidad:
MCE Japan Authorized Agent: